Last update 01 Nov 2024

Durcabtagene autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-BCMA CAR-T Cell Therapy - Novartis Pharmaceuticals, a B-cell maturation antigen (BCMA)-directed, genetically engineered T cell immunotherapy product derived from an autologous leukapheresis
+ [1]
Target
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 2
AU
03 Mar 2022
Relapse multiple myelomaPhase 2
GR
03 Mar 2022
Relapse multiple myelomaPhase 2
IL
03 Mar 2022
Relapse multiple myelomaPhase 2
BR
03 Mar 2022
Relapse multiple myelomaPhase 2
ES
03 Mar 2022
Relapse multiple myelomaPhase 2
DE
03 Mar 2022
Relapse multiple myelomaPhase 2
FR
03 Mar 2022
Relapse multiple myelomaPhase 2
CA
03 Mar 2022
Relapse multiple myelomaPhase 2
US
03 Mar 2022
Relapse multiple myelomaPhase 2
JP
03 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Multiple Myeloma
sBCMA | circulating EVs
19
xfwubwvuni(encsenmxuy) = The presence of BCMA was observed and quantified in circulating EVs (these EVs were characterized by canonical EV-associated proteins). In most patients, the BCMA-content of plasma EVs showed a similar dynamic profile to that shown by sBCMA. izpctjhrcj (lbantdvzwk )
-
14 May 2024
Phase 1
46
(nrctxakalp) = Dose limiting toxicities were experienced by 13% of pts and included gr 4 neutropenia, gr 4 lipase increase, gr 3 serum amylase increase, gr 3 neurotoxicity, gr 3 transaminitis, and gr 3 ejection fraction reduction. osyyanexsj (nmughexapl )
Positive
26 May 2023
Phase 1
22
(yyffvvtzwk) = yzbyfmjjdb bkadkpmnwp (fnrnvzavml )
Positive
12 May 2022
Phase 1
7
PHE-885
(mnctfvuseb) = lqtgmndxyr ezgmawltmc (mrgmcgnavy )
Positive
05 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free